Your account is not claimed yet. You can sign up with ORCID to claim your account.

Markus A Seeliger (Markus Seeliger)

ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 22

Top Venues

Biochemical Society transactions

Biochemistry

Cells

eLife

Stony Brook University

University of Cambridge (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Stony Brook University Sep 1o 2009

United States

Assistant Professor :: Pharmacological Sciences

Education History

University of Cambridge Oct 1o 1999 - Sep 30o 2003

United Kingdom

PHD :: Chemistry

Publications

Yağmur Kan, YiTing Paung, Markus A Seeliger, W Todd Miller
Domain Architecture of the Nonreceptor Tyrosine Kinase Ack1. Cells 12 (6) (2023)
Yağmur Kan, YiTing Paung, Yun-Young Kim, Markus A Seeliger, W Todd Miller
Biochemical Studies of Systemic Lupus Erythematosus-Associated Mutations in Nonreceptor Tyrosine Kinases Ack1 and Brk. Biochemistry 62 (6) (2023)
Yağmur Kan, YiTing Paung, Yun-Young Kim, Markus A Seeliger, W Todd Miller
Biochemical Studies of Systemic Lupus Erythematosus-Associated Mutations in Nonreceptor Tyrosine Kinases Ack1 and Brk. Biochemistry (2023)
Yağmur Kan, YiTing Paung, Markus A Seeliger, W Todd Miller
Domain Architecture of the Nonreceptor Tyrosine Kinase Ack1. Cells 12 (6) (2023)
Yağmur Kan, YiTing Paung, Markus A Seeliger, W Todd Miller
Domain Architecture of the Nonreceptor Tyrosine Kinase Ack1. Cells 12 (6) (2023)
Victoria R Mingione, YiTing Paung, Ian R Outhwaite, Markus A Seeliger
Allosteric regulation and inhibition of protein kinases. Biochemical Society transactions 51 (1) (2023)
Ian R Outhwaite, Markus A Seeliger
Probing conformational dynamics to understand kinase inhibition. eLife 12 (2023)
Ian R Outhwaite, Sukrit Singh, Benedict-Tilman Berger, Stefan Knapp, John D Chodera, Markus A Seeliger
Death by a thousand cuts through kinase inhibitor combinations that maximize selectivity and enable rational multitargeting. eLife 12 (2023)
Yağmur Kan, YiTing Paung, Yun-Young Kim, Markus A Seeliger, W Todd Miller
Biochemical Studies of Systemic Lupus Erythematosus-Associated Mutations in Nonreceptor Tyrosine Kinases Ack1 and Brk. Biochemistry 62 (6) (2023)
Victoria R Mingione, YiTing Paung, Ian R Outhwaite, Markus A Seeliger
Allosteric regulation and inhibition of protein kinases. Biochemical Society transactions 51 (1) (2023)
Pelin Ayaz, Agatha Lyczek, YiTing Paung, Victoria R Mingione, Roxana E Iacob, Parker W de Waal, John R Engen, Markus A Seeliger, Yibing Shan, David E Shaw
Structural mechanism of a drug-binding process involving a large conformational change of the protein target. Nature communications 14 (1) (2023)
Victoria R Mingione, YiTing Paung, Ian R Outhwaite, Markus A Seeliger
Allosteric regulation and inhibition of protein kinases. Biochemical Society transactions (2023)
Victoria R Mingione, YiTing Paung, Ian R Outhwaite, Markus A Seeliger
Allosteric regulation and inhibition of protein kinases. Biochemical Society transactions 51 (1) (2023)
Aziz M Rangwala, Benedict-Tilmann Berger, Matthew B Robers, Stefan Knapp, Markus A Seeliger
Resistance to kinase inhibition through shortened target engagement. Molecular & cellular oncology 9 (1) (2022)
Alexander A Peterson, Aziz M Rangwala, Manish K Thakur, Patrick S Ward, Christie Hung, Ian R Outhwaite, Alix I Chan, Dmitry L Usanov, Vamsi K Mootha, Markus A Seeliger, David R Liu
Discovery and molecular basis of subtype-selective cyclophilin inhibitors. Nature chemical biology 18 (11) (2022)
Mrinal Shekhar, Zachary Smith, Markus A Seeliger, Pratyush Tiwary
Protein Flexibility and Dissociation Pathway Differentiation Can Explain Onset of Resistance Mutations in Kinases. Angewandte Chemie (International ed. in English) 61 (28) (2022)
Dhivya Sridaran, Surbhi Chouhan, Kiran Mahajan, Arun Renganathan, Cody Weimholt, Shambhavi Bhagwat, Melissa Reimers, Eric H Kim, Manish K Thakur, Muhammad A Saeed, Russell K Pachynski, Markus A Seeliger, W Todd Miller, Felix Y Feng, Nupam P Mahajan
Inhibiting ACK1-mediated phosphorylation of C-terminal Src kinase counteracts prostate cancer immune checkpoint blockade resistance. Nature communications 13 (1) (2022)
Aziz M Rangwala, Victoria R Mingione, George Georghiou, Markus A Seeliger
Kinases on Double Duty: A Review of UniProtKB Annotated Bifunctionality within the Kinome. Biomolecules 12 (5) (2022)
Kevin Lou, Douglas R Wassarman, Tangpo Yang, YiTing Paung, Ziyang Zhang, Thomas A O'Loughlin, Megan K Moore, Regina K Egan, Patricia Greninger, Cyril H Benes, Markus A Seeliger, Jack Taunton, Luke A Gilbert, Kevan M Shokat
IFITM proteins assist cellular uptake of diverse linked chemotypes. Science (New York, N.Y.) 378 (6624) (2022)
Agatha Lyczek, Benedict-Tilman Berger, Aziz M Rangwala, YiTing Paung, Jessica Tom, Hannah Philipose, Jiaye Guo, Steven K Albanese, Matthew B Robers, Stefan Knapp, John D Chodera, Markus A Seeliger
Mutation in Abl kinase with altered drug-binding kinetics indicates a novel mechanism of imatinib resistance. Proceedings of the National Academy of Sciences of the United States of America 118 (46) (2021)
Linglan Fang, Jessica Vilas-Boas, Sujata Chakraborty, Zachary E Potter, Ames C Register, Markus A Seeliger, Dustin J Maly
How ATP-Competitive Inhibitors Allosterically Modulate Tyrosine Kinases That Contain a Src-like Regulatory Architecture. ACS chemical biology 15 (7) (2020)
Jingming Wang, Bryan Chan, Michael Tong, YiTing Paung, Ukhyun Jo, Dwight Martin, Markus A Seeliger, John D Haley, Hyungjin Kim
Prolyl isomerization of FAAP20 catalyzed by PIN1 regulates the Fanconi anemia pathway. PLoS genetics 15 (2) (2019)

Markus A Seeliger.css-eqlu8i{font-size:small;padding-left:4px;} (Markus Seeliger)

Publication Activity (10 Years)

Top Topics

Top Venues

Markus A Seeliger (Markus Seeliger)